Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two agents, L-arginine and bromocriptine. Bromocriptine is an ergot alkaloid derivative and a dopamine D2 receptor agonist, used primarily for the treatment of hyperprolactinemia, acromegaly, Parkinson's disease, and type 2 diabetes. It acts by stimulating dopamine receptors in the brain to lower prolactin levels, reduce growth hormone secretion, improve motor symptoms in Parkinson’s disease, and enhance insulin sensitivity without increasing insulin levels[1][2][5]. L-arginine is a semi-essential amino acid that serves as a precursor for nitric oxide synthesis and plays roles in immune function and vascular health. In preclinical studies (rat models), the combination of bromocriptine with L-arginine has shown potential to reduce early neoplastic changes in liver carcinogenesis associated with diabetes—possibly via activation of AMP-activated protein kinase (AMPK), which acts as a metabolic tumor suppressor[4]. This combination is not an established or approved pharmaceutical product but has been studied experimentally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine + bromocriptine.